INCRAFT腹主动脉瘤超低剖面覆膜支架系统治疗后血栓栓塞并发症
回顾性研究纳入单中心80例于2015年2月至2022年12月接受INCRAFT超低剖面覆膜支架治疗肾下腹主动脉瘤的患者,独立复核影像评估血栓栓塞事件。肢体移植物闭塞发生于7例(9%)患者、12条肢体(7.5%),1、3、5年一期通畅率分别为96%、94%、89%,二期通畅率分别为99%、97%、93%。支架内血栓见于36%患者并累及93%的支架肢体,8例(10.0%)共10处远端闭塞被认为源于支架内血栓;支架内血栓与肢体移植物闭塞显著相关(比值比77.10,P=.003)。
要点
- 肢体移植物闭塞发生于7例(9%)患者、12条肢体(7.5%)。
- 支架内血栓见于36%患者,并累及93%的支架肢体。
- 支架内血栓与肢体移植物闭塞显著相关(比值比77.10,P=.003)。
核心结论
- INCRAFT覆膜支架治疗后血栓栓塞事件常见,肢体移植物闭塞率按患者计为9%,支架内血栓见于36%患者。
- 支架内血栓在70岁及以下患者中更常见,且是肢体移植物闭塞的显著危险因素。
研究设计与样本
- 单中心回顾性研究,纳入2015年2月至2022年12月接受INCRAFT覆膜支架治疗肾下腹主动脉瘤的80例患者。
- 所有可用影像学检查由两名阅片者独立复核;采用回归分析评估与血栓栓塞事件相关的可能危险因素。
主要发现
- 肢体闭塞发生于7例患者(9%)、12条肢体(7.5%)。
- 1、3、5年一期通畅率分别为96%、94%、89%,二期通畅率分别为99%、97%、93%。
- 支架内血栓见于36%患者,并累及93%的支架肢体。
- 8例患者(10.0%)共10处远端闭塞被认为源于支架内血栓,所有患者均出现膝下血管症状性闭塞。
- 支架内血栓1、3、4年无事件率分别为80%、61%、43%;年龄≤70岁和入路血管直径≥10 mm与支架内血栓发生相关;支架内血栓与肢体移植物闭塞显著相关(比值比77.10,P=.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-profile endografts have reported increased rates of limb graft occlusions. The INCRAFT stent graft system is an ultra-low-profile endograft for the exclusion of infrarenal abdominal aortic aneurysms. Our aim was to report thromboembolic events (TEs) in patients treated with the INCRAFT device and its association with risk factors. METHODS: A retrospective study was performed of 80 patients treated with the INCRAFT endograft between February 2015 and December 2022 at a single institution. All available imaging studies were reviewed by two reviewers independently. TEs included intraprosthetic thrombus (IPT), limb graft occlusion (LGO), and distal embolization. A regression analysis was performed to evaluate possible risk factors associated with the development of TEs. These included tortuous access vessels, IPT, access vessel diameter, and the ratio between the cross-sectional area of the main body to the bilateral limb grafts. RESULTS: Limb occlusions occurred in seven patients (9%) and 12 limbs (7.5%), resulting in a primary and secondary patency at 1, 3, and 5 years of 96% and 99%, 94% and 97%, and 89% and 93%, respectively. IPT was found in 36% of patients and affected endograft limbs in 93%. Ten distal occlusions in eight patients (10.0%) were considered to originate from IPT, which led to symptomatic occlusions of below-the-knee vessels in all patients. Freedom from IPT at 1, 3, and 4 years was 80%, 61%, and 43%, respectively. Age ≤70 years and access vessel diameter ≥10 mm were associated with IPT development. IPT was significantly associated with LGO (odds ratio, 77.10; P = .003). CONCLUSIONS: Thromboembolic events are frequent after treatment with the INCRAFT endograft with a LGO rate of 9% per patient and IPT found in 36% of patients. IPT was more common in patients ≤70 years and was a significant risk factor for LGO.
引用
- Papazoglou DD, Béguin M, Ricchiuto M, et al. Thromboembolic complications after treatment with the INCRAFT abdominal aortic aneurysm ultra-low-profile stent graft system. J Vasc Surg. 2025. PMID: 39800117. doi:10.1016/j.jvs.2025.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。